, Tracking Stock Market Picks
Enter Symbol:
Alnylam Pharmaceuticals, Inc. (ALNY) [hlAlert]

up 966.05 %

Alnylam Pharmaceuticals, Inc. (ALNY) rated Buy with price target $15 by MLV Capital

Posted on: Friday,  May 6, 2011  9:25 AM ET by MLV Capital

MLV Capital rated Buy Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on 05/06/2011, when the stock price was $9.84. Since
then, Alnylam Pharmaceuticals, Inc. has gained 966.06% as of 01/22/2016's recent price of $104.90.
If you would have followed this MLV Capital's recommendation on ALNY, you would have gained 966.05% of your investment in 1722 days.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.

MLV Capital is a boutique investment bank and institutional broker-dealer focused on providing independent financial advice and unique capital markets expertise to corporate and institutional clients in capital intensive industries such as metals and mining, life sciences, energy and real estate. With a focus on raising money efficiently for clients, MLV has rapidly become a leader in the At-the-Market(ATM) transaction market.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/6/2011 9:25 AM Buy
9.84 15.00
as of 12/30/2011
1 Week down  -0.48 %
1 Month up  14.78 %
3 Months up  24.04 %
1 YTD down  -17.17 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy